Pharmacokinetic evaluation of frovatriptan

Bibliography

• Cady R, Schreiber C. Sumatriptan: update and review. Expert Opin Pharmacother 2006;7:1503-14
   PubMed Web of Science ®Google Scholar
• Buchan P, Keywood C, Wade A, Ward C. Clinical pharmacokinetics of frovatriptan. Headache 2002;42(Suppl 2):S54-62
   PubMedGoogle Scholar
• Lipton RB. Disability assessment as a basis for stratified care. Cephalalgia 1998;18(Suppl 22):40-3
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Triptans (serotonin 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Tepper SJ, Bigal ME, The triptan formulations. How to match patients and products. CNS Drugs 2003;17:431-47
   PubMed Web of Science ®Google Scholar
• Lucas C. Strategies to improve migraine treatment results. Drugs 2006;66(Suppl 3):9-16
   Google Scholar
• Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010;70:1505-18
   PubMed Web of Science ®Google Scholar
• Belvis R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Patent CNS Drug Discov 2009;4:70-81
   PubMedGoogle Scholar
• Dahlof CG. Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache Rep 2005;9:206-12
   PubMedGoogle Scholar
• Helfand M, Peterson K. Drug class review: triptans: final report update 4. Portland (OR): Oregon Health & Science University 2009;1-264
   Google Scholar
• Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003;2:123-7
   PubMedGoogle Scholar
• Loder E. Triptan therapy in migraine. N Engl J Med 2010;363:63-70
   PubMed Web of Science ®Google Scholar
• Gawel MJ, Worthington I, Maggisano A. A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 2001;28:30-41
   PubMed Web of Science ®Google Scholar
• Gentile G, Borro M, Lala N, Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 2010;11:431-5
   PubMed Web of Science ®Google Scholar
• Gentile G, Missori S, Borro M, Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 2010;11:151-6
   PubMed Web of Science ®Google Scholar
• Napier C, Stewart M, Melrose H, Characterization of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999;368:259-68
   PubMed Web of Science ®Google Scholar
• Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43:376-88
   PubMed Web of Science ®Google Scholar
• McHarg AD, Napier CM, Stewart M, The functional activity of eletriptan and other 5-HT1B/1D agonists at the human recombinant 5-HT1B and 5-HT1D receptor. Headache 1999;39:369-70
   Google Scholar
• Jahnichen S, Radtke OA, Pertz HH. Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery. Naunyn Schmiedebergs Arch Pharmacol 2004;370:54-63
   PubMed Web of Science ®Google Scholar
• Comer MB. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Headache 2002;42(Suppl 2):S47-53
   PubMedGoogle Scholar
• Van den Broek RWM, Bhalla P, MaassenVanDenBrink A, Characterization of sumatriptan induced contractions in human isolated blood vessels using selective 5-HT1B and 5-HT1D receptor antagonists and in situ hybridization. Cephalalgia 2002;22:83-93
   PubMed Web of Science ®Google Scholar
• Graul A, Leson P, Castaner J. SB-209509/VML-251. Drugs Future 1997;22:725-8
   Google Scholar
• Ferrari MD. Migraine. Lancet 1998;351:1043-51
   PubMed Web of Science ®Google Scholar
• Eglen RM, Jasper JR, Chang DJ, The 5-HT7 receptor: orphan found. Trends Pharmacol Sci 1997;18:104-7
   PubMed Web of Science ®Google Scholar
• Tfelt Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-87
   PubMed Web of Science ®Google Scholar
• Parsons AA, Raval P, Smith S, Effects of the novel high-affinity 5-HT(1B 1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol 1998;32:220-4
   PubMed Web of Science ®Google Scholar
• Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002;112:135-40
   PubMed Web of Science ®Google Scholar
• Elkind AH, Satin LZ, Nila A, Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache 2004;44:403-10
   PubMed Web of Science ®Google Scholar
• Elkind AH, Wade A, Ishkanian G. Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol 2004;44:1158-65
   PubMed Web of Science ®Google Scholar
• Bigal ME, Bordini CA, Antoniazzi AL, Speciali JG. The triptan formulations: a critical evaluation. Arq Neuropsiquiatr 2003;61:313-20
   PubMed Web of Science ®Google Scholar
• Rapoport A, Ryan R, Goldstein J, Keywood C. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache 2002;42(Suppl 2):S74-83
   PubMed Web of Science ®Google Scholar
• Goldstein J, Keywood C. Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache 2002;42:41-8
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Reekers M, Bax WA, Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30
   PubMed Web of Science ®Google Scholar
• Parsons AA, Parker SG, Raval P, Comparison of the cardiovascular effects of the novel 5-HT1B/1D receptor agonist SB 209509 (VML 251) and sumatriptan in dogs. J Cardiovasc Pharmacol 1997;30:136-41
   PubMed Web of Science ®Google Scholar
• Parsons AA, Valocik R, Koster P, Effects of the novel antimigraine agent, frovatriptan, on coronary and cardiac function in dogs. J Cardiovasc Pharmacol 1998;32:995-1000
   PubMed Web of Science ®Google Scholar
• Carel I, Ghaleh B, Edouard A, Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs. Br J Pharmacol 2001;132:1071-83
   PubMed Web of Science ®Google Scholar
• Ryan R, Geraud G, Goldstein J, Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002;42(Suppl 2):S84-92
   PubMed Web of Science ®Google Scholar
• Poolsup N, Leelasangaluk V, Jittangtrong J, Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 2005;30:521-32
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment. J Headache Pain 2011;12:275-80
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Parenteral versus oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. J Headache Pain 2007;8:273-6
   PubMedGoogle Scholar
• Spierings EL, Keywood C. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study. Pain Med 2009;10:633-8
   PubMed Web of Science ®Google Scholar
• Wallasch T-M. Frovatriptan in the practice of office-based neurologists and pain therapists: the ALADIN study. Adv Ther 2010;27:56-62
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Spierings ELH. Acute treatment of migraine attacks: frovatriptan 2.5mg an effective and economical alternative. Nervenheilkunde 2004;23:545-8
   Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Gentry P, Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 2000;40:464-5
   PubMed Web of Science ®Google Scholar
• Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31
   PubMed Web of Science ®Google Scholar
• Pascual J, Diener HC, Massiou H. Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. J Headache Pain 2006;7:27-33
   PubMedGoogle Scholar
• Hutchison J, Pfaffenrath V, Geraud G. A randomized, placebo-controlled, parallel-group trial of frovatriptan and sumatriptan for a single acute migraine attack [letter]. Eur J Neurol 2007;14(Suppl 1):144
   PubMedGoogle Scholar
• Tullo V, Allais G, Ferrari MD, Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci 2010;31(Suppl 1):S51-4
   PubMedGoogle Scholar
• Savi L, Omboni S, Lisotto C, A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain 2011;12:219-26
   PubMed Web of Science ®Google Scholar
• Bartolini M, Giamberardino MA, Lisotto C, A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 2011;12:361-8
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
   PubMedGoogle Scholar
• Guidotti M, Ravasio R. Clinical and economic comparison of frovatriptan versus other oral triptans in the treatment of acute migraine in the real-world setting. Clin Drug Investig 2009;29:693-702
   PubMed Web of Science ®Google Scholar
• Tfelt-hansen P. When to use frovatriptan in migraine? J Headache Pain 2011;12:393-4
   PubMed Web of Science ®Google Scholar
• Fierro B, Omboni S, Bertolini M, When to use frovatriptan? A reply. J Headache Pain 2011;12:395-6
   Web of Science ®Google Scholar
• Saxena PR, Tfelt-hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-hansen P, Welch KMA. editors. The Headaches. 3rd edition. Lippincott Williams & Wilkins; Philadelphia: 2006. p. 469-503
   Google Scholar
• Lipton RB, Bigal ME, Diamond M, Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• Granella F, Sances G, Zanferrari C, Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993;33:385-9
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Cabarrocas X, Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci 2006;27(Suppl 2):S193-7
   PubMed Web of Science ®Google Scholar
• Tuchman M, Hee A, Emeribe U, Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs 2006;20:1019-26
   PubMed Web of Science ®Google Scholar
• Mannix LK, Loder E, Nett R, Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia 2007;27:414-21
   PubMed Web of Science ®Google Scholar
• Mannix LK, Savani N, Landy S, Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007;47:1037-49
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Keywood C. Frovatriptan is effective in menstrually associated migraine. Cephalalgia 2000;20:345-8
   Google Scholar
• Brandes JL, Poole AC, Kallela M, Short-term frovatriptan for the prevention of difficult to-treat menstrual migraine attacks. Cephalalgia 2009;29:1133-48
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261-9
   PubMed Web of Science ®Google Scholar
• Pageler L, Katsarava Z, Lampl C, Frovatriptan for prophylactic treatment of cluster headache: lessons for future trial design. Headache 2011;51:129-34
   PubMed Web of Science ®Google Scholar
• Lipton RB, Micieli G, Russell D, Guidelines for controlled trials of drugs in cluster headache. Cephalalgia 1995;15:452-62
   PubMed Web of Science ®Google Scholar
• Latsko M, Silberstein S, Rosen N. Frovatriptan as preemptive treatment for fasting-induced migraine. Headache 2011;51:369-74
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M. Clinical use of triptans in the management of migraine. CNS Drugs 2006;20(Suppl 1):12-23
   PubMedGoogle Scholar
• Bigal ME, Krymchantowski AV, Ho T. Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arq Neuropsiquiatr 2009;67:559-69
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Pharmacological profile and clinical characteristics of frovatriptan in the acute treatment of migraine: introduction. Headache 2002;42(Suppl 2):S45-6
   PubMedGoogle Scholar
• Markus F, Mikko K. Frovatriptan review. Expert Opin Pharmacother 2007;8:3029-33
   PubMed Web of Science ®Google Scholar
• Balbisi EA. Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract 2004;58:695-705
   PubMed Web of Science ®Google Scholar
• Buchan P, Wade A, Ward C, Frovatriptan: a review of drug-drug interactions. Headache 2002;42(Suppl2):S63-73
   PubMedGoogle Scholar
• Balbisi EA. Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag 2006;2:303-8
   PubMedGoogle Scholar
• Allais G, Bussone G, De Lorenzo C, Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. Neurol Sci 2005;26(Suppl 2):S125-9
   PubMedGoogle Scholar
• Steiner TJ, Birbeck GL, Jensen R, The Global Campaign, World Health Organization and Lifting The Burden: collaboration in action. J Headache Pain 2011;12:273-4
   PubMed Web of Science ®Google Scholar